Regen BioPharma (RGBP) 10-K21 Jun 212019 FY Annual reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Sep. 30, 2019	May 14, 2021	Mar. 31, 2019
Document And Entity Information
Entity Registrant Name	Regen BioPharma Inc
Entity Central Index Key	0001589150
Document Type	10-K
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Public Float			$ 7,330,721
Entity Common Stock, Shares Outstanding		3,746,423,788
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Interactive Data Current	No
Entity Incorporation, State or Country Code	NV
Entity File Number	333-191725

CONSOLIDATED CONDENSED BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2019	Sep. 30, 2018
CURRENT ASSETS
Cash	$ 7,855	$ 8,019
Accounts Receivable, Related Party	71,186	0
Note Receivable, Related Party	0	4,551
Prepaid Expenses	76	8,259
Accrued Interest Receivable, Related Partry	0	7,672
Prepaid Rent	0	14,270
Total Current Assets	79,117	42,771
Investment Securities, Related Party	19,969	166,247
Total Other Assets	19,969	166,247
TOTAL ASSETS	99,087	209,018
Current Liabilities:
Bank Overdraft	0	203
Accounts payable	92,000	80,567
Notes Payable	88,627	227
Accrued payroll taxes	4,241	4,241
Accrued Interest	525,335	292,094
Accrued Rent	5,000	0
Accrued Payroll	972,158	655,663
Other Accrued Expenses	41,423	41,243
Due to Investor	20,000	20,000
Derivative Liability	7,200,528	6,736,607
Convertible Notes Payable Less unamortized discount	2,051,537	774,666
Unearned Income	0	68,000
Convertible Notes Payable, Related Parties Less unamortized discount	2,056	0
Total Current Liabilities	11,002,904	8,673,511
Long Term Liabilities:
Convertible Notes Payable less unamortized discount	0	656,272
Convertible Notes Payable, Related Parties Less unamortized discount	4,978	906
Total Long Term Liabilities	4,978	657,178
Total Liabilities	11,007,882	9,330,689
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 180,315,107 issued and outstanding as of September 30, 2018 and 4,800,000,000 authorized and 600,001,406 shares issued and outstanding September 30, 2019	59,998	18,030
Additional Paid in capital	8,261,993	7,517,888
Contributed Capital	728,658	728,658
Retained Earnings (Deficit)	(19,998,086)	(17,457,044)
Accumulated Other Comprehensive Income	0	52,948
Shareholders Equity Regen Biopharma	(10,908,795)	(9,121,671)
Non Controlling Interest KCL Therapeutics	0	0
Total Stockholders' Equity (Deficit)	(10,908,795)	(9,121,671)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	99,087	209,018
Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock Value	34,838	14,044
Series AA Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock Value	5	0
Series M Preferred Stock [Member]
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock Value	$ 3,800	$ 3,800

CONSOLIDATED CONDENSED BALANC_2

CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Sep. 30, 2018
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	4,800,000,000	500,000,000
Common stock, shares issued	600,001,406	180,315,107
Common stock, shares outstanding	600,001,406	180,315,107
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	800,000,000	800,000,000
Series A Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares issued	348,376,230	140,434,496
Preferred stock, shares outstanding	348,376,230	140,434,496
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares issued	50,000	50,000
Preferred stock, shares outstanding	50,000	50,000
Series M Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares issued	38,000,000	38,000,000
Preferred stock, shares outstanding	38,000,000	38,000,000

CONSOLIDATED CONDENSED STATEMEN

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($)	Sep. 30, 2019	Sep. 30, 2018
REVENUES
Revenues, Related Party	$ 110,000	$ 100,000
COST AND EXPENSES
Research and Development	45,605	374,436
General and Administrative	500,640	743,755
Consulting and Professional Fees	260,540	347,592
Rent	60,000	60,000
Total Costs and Expenses	866,785	1,525,783
OPERATING INCOME (LOSS)	(756,785)	(1,425,783)
OTHER INCOME & (EXPENSES)
Interest Income, Related Party	1,302	10,234
Other Income	1,616	0
Dividend Income	0	5,741
Loss on Sale of Securities	(57,697)	0
Unrealized (Gain) Loss on Investment Securities, Related Party	(51,844)	0
Interest Expense	(295,167)	(259,069)
Refunds of amounts previously paid	115	96
Interest Expense attributable to Amortization of Discount	(1,407,089)	(1,304,288)
Gain (Loss) on Early Extinguishment Convertible Debt	69,945	(103,866)
Bad Debt Expense	(118,121)	0
Other Than Temporary Impairment Recognized	0	(270,294)
Derivative Income (Expense)	(705)	(1,367,971)
TOTAL OTHER INCOME (EXPENSE)	(1,866,390)	(3,289,417)
NET INCOME (LOSS)	(2,623,176)	(4,715,200)
NET INCOME (LOSS) attributable to common shareholders	$ (2,623,176)	$ (4,715,200)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.0013)	$ (0.0310)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	2,071,155,682	152,091,330

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDER'S EQUITY - USD ($)	Series A Preferred stock	Series AA Preferred stock	Common Stock	Series M Preferred stock	Additional Paid-In Capital	Retained Earnings	Contributed Capital	Other Comprehensive Income (Loss)	Total
Beginning balance, Shares at Sep. 30, 2017	136,966,697	50,000	139,704,157	32,000,000
Beginning balance, Amount at Sep. 30, 2017	$ 13,697	$ 5	$ 13,969	$ 3,200	$ 6,642,979	$ (12,741,843)	$ 728,658	$ 88,000	$ (5,251,335)
Common Shares issued for debt, Shares			3,976,852
Common Shares issued for debt, Amount			$ 398		85,502				85,900
Common Shares issued to Consultant, Shares				2,000,000
Common Shares issued to Consultant, Amount				$ 200					200
Preferred Shares issued to Consultant, Shares				4,000,000
Preferred Shares issued to Consultant, Amount				$ 400					400
Unrealized Gain (Loss) on Securities Available for Sale								40,000	40,000
Net Income (loss)						(2,785,149)			(2,785,149)
Ending balance, Shares at Dec. 31, 2017	136,966,697	50,000	146,181,009	38,000,000
Ending balance, Amount at Dec. 31, 2017	$ 13,697	$ 5	$ 14,617	$ 3,800	6,837,981	(15,526,990)	728,658	128,000	(7,800,232)
Common Shares issued for debt, Shares			332,955
Common Shares issued for debt, Amount			$ 33		10,376				10,409
Common Shares issued for Debt, Shares			522,255
Common Shares issued for Debt, Amount			$ 52		13,560				13,612
Preferred Shares Purchased for Cash, Shares	2,500,000
Preferred Shares Purchased for Cash, Amount	$ 250				24,750				25,000
Common Shares Purchased for Cash, Shares			2,500,000
Common Shares Purchased for Cash, Amount			$ 250		24,750				25,000
Common Shares issued for Debt, Shares			796,254
Common Shares issued for Debt, Amount			$ 80		18,862				18,942
Common Shares issued for Debt, Shares			744,948
Common Shares issued for Debt, Amount			$ 74		12,613				12,687
Common Shares issued to Consultant, Shares			250,000
Common Shares issued to Consultant, Amount			$ 25		7,900				7,925
Unrealized Gain (Loss) on Securities Available for Sale								(19,200)	(19,200)
Net Income (loss)						(840,851)			(840,851)
Ending balance, Shares at Mar. 31, 2018	139,466,697	50,000	151,327,421	38,000,000
Ending balance, Amount at Mar. 31, 2018	$ 13,947	$ 5	$ 15,131	$ 3,800	6,950,792	(16,367,844)	728,658	108,800	(8,546,711)
Common Shares issued for debt, Shares			785,237
Common Shares issued for debt, Amount			$ 79		12,681				12,760
Preferred Stock issued for Debt, Shares	40,080
Preferred Stock issued for Debt, Amount	$ 4				1,038				1,042
Common Shares issued for Debt, Shares			363,597
Common Shares issued for Debt, Amount			$ 36		5,163				5,199
Common Shares issued for Debt, Shares			403,583
Common Shares issued for Debt, Amount			$ 40		5,206				5,246
Preferred Stock issued for Debt, Shares	108,004
Preferred Stock issued for Debt, Amount	$ 11				2,095				2,106
Preferred Stock issued for Debt, Shares	146,407
Preferred Stock issued for Debt, Amount	$ 15				2,097				2,112
Common Shares issued for Debt, Shares			405,858
Common Shares issued for Debt, Amount			$ 41		5,235				5,276
Common Shares issued for Debt, Shares			728,390
Common Shares issued for Debt, Amount			$ 73		10,674				10,747
Preferred Stock issued for Debt, Shares	181,018
Preferred Stock issued for Debt, Amount	$ 18				2,099				2,117
Common Shares issued for Debt, Shares			4,712,320
Common Shares issued for Debt, Amount			$ 471		58,433				58,904
Unrealized Gain (Loss) on Securities Available for Sale								(18,400)	(18,400)
Net Income (loss)						(107,596)			(107,596)
Ending balance, Shares at Jun. 30, 2018	139,942,206	50,000	158,726,406	38,000,000
Ending balance, Amount at Jun. 30, 2018	$ 13,994	$ 5	$ 15,871	$ 3,800	7,055,513	(16,475,440)	728,658	90,400	(8,567,198)
Common Shares issued for debt, Shares			451,629
Common Shares issued for debt, Amount			$ 45		5,268				5,313
Preferred Stock issued for Debt, Shares	492,290
Preferred Stock issued for Debt, Amount	$ 49				3,150				3,199
Common Shares issued for Debt, Shares			3,630,753
Common Shares issued for Debt, Amount			$ 363		37,160				37,523
Common Shares issued for Debt, Shares			7,500,000
Common Shares issued for Debt, Amount			$ 750		55,500				56,250
Common Shares issued for Debt, Shares			659,760
Common Shares issued for Debt, Amount			$ 66		5,294				5,360
Cancellation of Common Shares, Shares			(3,976,852)
Cancellation of Common Shares, Amount			$ (398)		(85,502)				(85,900)
Common Shares issued for Debt, Shares			4,273,504
Common Shares issued for Debt, Amount			$ 427		29,573				30,000
Common Shares issued for Debt, Shares			7,720,407
Common Shares issued for Debt, Amount			$ 772		53,425				54,197
Common Shares issued for Debt, Shares			1,329,500
Common Shares issued for Debt, Amount			$ 133		8,508				8,641
Beneficial Conversion Feature Recognized					350,000				350,000
Unrealized Gain (Loss) on Securities Available for Sale								(37,452)	(37,452)
Net Income (loss)						(981,602)			(981,602)
Ending balance, Shares at Sep. 30, 2018	140,434,496	50,000	180,315,107	38,000,000
Ending balance, Amount at Sep. 30, 2018	$ 14,044	$ 5	$ 18,030	$ 3,800	7,517,888	(17,457,044)	728,658	52,948	(9,121,671)
Shares issued for debt, Shares			5,128,205
Shares issued for debt, Amount			$ 513		29,487				30,000
Shares issued for debt, Shares			8,961,988
Shares issued for debt, Amount			$ 896		29,754				30,650
Shares issued for debt, Shares			2,019,140
Shares issued for debt, Amount			$ 202		7,410				7,612
Shares issued for debt, Shares			3,015,618
Shares issued for debt, Amount			$ 302		11,066				11,368
Shares issued for debt, Shares			7,100,591
Shares issued for debt, Amount			$ 710		29,290				30,000
Shares issued for debt, Shares	3,656,020
Shares issued for debt, Amount	$ 366				5,099				5,465
Shares issued for debt, Shares			29,033,181
Shares issued for debt, Amount			$ 2,903		47,813				50,716
Shares issued for expenses, Shares			286,232
Shares issued for expenses, Amount			$ 29		471				500
Shares issued for debt, Shares			5,184,674
Shares issued for debt, Amount			$ 518		9,929				10,447
Shares issued for debt, Shares			10,382,717
Shares issued for debt, Amount			$ 1,038		7,372				8,410
Shares issued for expenses, Shares			617,283
Shares issued for expenses, Amount			$ 62		438				500
Derecognition of Accumulated Other Comprehensive Income						52,948		(52,948)	0
Adjustment for noncontrolling Interest KCL Therapeutics, Inc.						29,186			29,186
Net Income (loss)						245,057			245,057
Ending balance, Shares at Dec. 31, 2018	144,090,516	50,000	252,044,737	38,000,000
Ending balance, Amount at Dec. 31, 2018	$ 14,409	$ 5	$ 25,203	$ 3,800	7,696,017	(17,129,853)	728,658	0	(8,661,761)
Shares issued for debt, Shares			10,585,123
Shares issued for debt, Amount			$ 1,059		12,692				13,751
Shares issued for services, Shares	10,000,000
Shares issued for services, Amount	$ 1,000				48,000				49,000
Shares issued for debt, Shares			5,774,947
Shares issued for debt, Amount			$ 577		6,555				7,132
Shares issued for debt, Shares			12,222,690
Shares issued for debt, Amount			$ 1,222		5,744				6,966
Shares issued for expenses, Shares			877,310
Shares issued for expenses, Amount			$ 88		412				500
Shares issued for debt, Shares			10,473,668
Shares issued for debt, Amount			$ 1,047		11,887				12,934
Shares issued for debt, Shares			13,821,193
Shares issued for debt, Amount			$ 1,382		14,374				15,756
Shares issued for debt, Shares			13,790,783
Shares issued for debt, Amount			$ 1,379		18,341				19,720
Shares issued for debt, Shares			8,004,463
Shares issued for debt, Amount			$ 800		7,844				8,644
Shares issued for expenses, Shares			694,508
Shares issued for expenses, Amount			$ 69		431				500
Shares issued for debt, Shares			14,305,492
Shares issued for debt, Amount			$ 1,431		8,868				10,299
Shares issued for expenses, Shares			833,449
Shares issued for expenses, Amount			$ 83		417				500
Shares issued for debt, Shares			27,377,166
Shares issued for debt, Amount			$ 2,738		19,766				22,504
Shares issued for debt, Shares			6,309,524
Shares issued for debt, Amount			$ 631		4,669				5,300
Shares of subsidiary issued for services					441				441
Adjustment for noncontrolling Interest KCL Therapeutics, Inc.					(2,934)				0
Net Income (loss)						(333,177)			(333,177)
Ending balance, Shares at Mar. 31, 2019	154,090,516	50,000	377,115,053	38,000,000
Ending balance, Amount at Mar. 31, 2019	$ 15,409	$ 5	$ 37,710	$ 3,800	7,853,523	(17,463,031)	728,658	0	(8,820,991)
Shares issued for debt, Shares			8,958,116
Shares issued for debt, Amount			$ 896		3,403				4,299
Shares issued for debt, Shares			12,992,389
Shares issued for debt, Amount			$ 1,299		8,055				9,354
Shares issued for debt, Shares			17,971,064
Shares issued for debt, Amount			$ 1,797		12,220				14,017
Shares issued for expenses, Shares			1,041,884
Shares issued for expenses, Amount			$ 104		396				500
Shares issued for debt, Shares			11,832,569
Shares issued for debt, Amount			$ 1,183		7,336				8,519
Shares issued for debt, Shares			19,472,820
Shares issued for debt, Amount			$ 1,947		13,241				15,188
Shares issued for debt, Shares			14,824,958
Shares issued for debt, Amount			$ 1,482		9,191				10,673
Shares issued for debt, Shares			22,243,153
Shares issued for debt, Amount			$ 2,224		15,125				17,349
Shares issued for expenses, Shares			1,041,884
Shares issued for expenses, Amount			$ 104		396				500
Shares issued for debt, Shares			8,958,116
Shares issued for debt, Amount			$ 896		3,403				4,299
Shares issued for debt, Shares			20,746,153
Shares issued for debt, Amount			$ 2,075		6,198				8,273
Shares issued for expenses, Shares			1,253,847
Shares issued for expenses, Amount			$ 125		375				500
Shares issued for debt, Shares	194,285,714
Shares issued for debt, Amount	$ 19,429				320,571				340,000
Adjustment for noncontrolling Interest KCL Therapeutics, Inc.					(12,708)
Net Income (loss)						(4,405,083)			(4,405,083)
Ending balance, Shares at Jun. 30, 2019	348,376,230		518,452,006	38,000,000
Ending balance, Amount at Jun. 30, 2019	$ 34,838		$ 51,843	$ 3,800	8,240,724	(21,868,114)	728,658	0	(12,792,604)
Shares issued for debt, Shares			9,758,664
Shares issued for debt, Amount			$ 976		1,073				2,049
Shares issued for interest, Shares			13,730,712
Shares issued for interest, Amount			$ 1,373		1,510				2,883
Shares issued for fees, Shares			2,381,324
Shares issued for fees, Amount			$ 238		262				500
Shares issued for debt, Shares			19,754,570
Shares issued for debt, Amount			$ 1,975		987				2,962
Shares issued for interest, Shares			4,073,588
Shares issued for interest, Amount			$ 407		204				611
Shares issued for debt, Shares			19,337,487
Shares issued for debt, Amount			$ 1,934		967				2,901
Common shares issued for interest, Shares			5,845,752
Common shares issued for interest, Amount			$ 585		292				877
Shares issued for fees, Shares			3,333,762
Shares issued for fees, Amount			$ 333		167				500
Common Shares issued for Expenses, Shares			3,333,542
Common Shares issued for Expenses, Amount			$ 333		167				500
Adjustment for noncontrolling Interest KCL Therapeutics, Inc.					15,642				0
Net Income (loss)						1,870,027			1,870,027
Ending balance, Shares at Sep. 30, 2019	348,376,230		600,001,406	38,000,000
Ending balance, Amount at Sep. 30, 2019	$ 34,838		$ 59,998	$ 3,800	$ 8,261,993	$ (19,998,086)	$ 728,658		$ (10,908,795)

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$ (2,623,176)	$ (4,715,200)
Adjustments to reconcile net Income to net cash
Preferred Stock issued to Consultants	49,000	600
Common Stock issued to consultants	0	150,510
Common Stock issued for interest	0	29,722
Preferred Stock Issued For Interest	0	579
Subsidiary Stock issued to consultants	46	0
Subsidiary Stock issued as compensation	294	0
Common Stock issued for Expenses	5,500	0
Increase (Decrease) in Interest expense attributable to amortization of Discount	1,407,089	1,304,288
(Gain) Loss on Sale of Investment Securities	57,697	0
Increase (Decrease) in Loss on early extinguishment of debt	(69,945)	103,866
Increase (Decrease) in Recognition of Other than Temporary Impairment	0	270,294
Unrealized (Gain) Loss on Investment Securities, Related Party	51,843	0
Increase (Decrease) in Accounts Payable	11,429	(415,190)
increase (Decrease) Unearned Income	(38,814)	68,000
(Increase) Decrease in Accounts Receivable	(71,186)	0
Increase (Decrease) in Accrued Expenses	603,275	247,693
(Increase) Decrease in Prepaid Expenses	13,284	(20,937)
Increase in Derivative Expense	705	1,367,971
(Increase) Decrease in Interest Receivable, Related Party	(1,303)	(10,234)
(Increase) Decrease in Notes Receivable, Related Party	4,551	40,000
Increase(Decrease) in Bad Debt Expense	118,121	0
Increase(Decrease) in Bank Overdraft	(203)	203
Net Cash Provided by (Used in) Operating Activities	(481,793)	(1,577,836)
Cash Flows from Investment Activities
Increase(Decrease) in Sale of Investment Securities	49,858	0
Net Cash Used in Investment Activities	49,858	(5,741)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash	0	25,000
Preferred Stock issued for Cash	0	25,000
Increase (Decrease) in Notes Payable	88,400	(111,128)
Increase in Convertible Notes Payable	343,371	1,382,750
Increase in Due to Investor	0	0
Net Cash Provided by (Used in) Financing Activities	431,771	1,321,622
Net Increase (Decrease) in Cash	(164)	(261,955)
Cash at Beginning of Period	8,018	269,973
Cash at End of Period	7,855	8,018
Supplemental Disclosure of Noncash Investing and Financing Activities:
Common Shares Issued for Debt	363,850	321,350
Preferred Shares Issued for Debt	345,000	10,000
Cash Paid for Interest	22,135	52,432
Common shares Issued for Interest	42,613	29,722
Preferred Shares issued for Interest	$ 0	$ 572

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
Organization and Summary of Significant Accounting Policies	Sep. 30, 2019
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was organized April 24, 2012 under the laws of the State of Nevada The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Black Scoles pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of June 30, 2019 utilized the following inputs: Risk Free Interest Rate 1.75 % Expected Term 0.042 – 1.59 Yrs Expected Volatility 207.11 – 273.20 % Expected Dividends C. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2019 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. D. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the years ended September 30, 2019 and 2018. F. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. G. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. H. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2019
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

Going Concern

Going Concern	12 Months Ended
Going Concern	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $19,998,086 during the period from April 24, 2012 (inception) through September 30, 2019. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise.

Notes Payable, Related Party

Notes Payable, Related Party	12 Months Ended
Notes Payable, Related Party	Sep. 30, 2019
Debt Disclosure [Abstract]
Notes Payable Related Party	NOTE 4. NOTES PAYABLE , RELATED PARTY As of September 30, 2019 David Koos $ 227 Zander Therapeutics, Inc. 64,400 BST Partners 24,000 Total: $ 88,627 $227 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum. As of September 30, 2019 Regen Biopharma Inc. is indebted to Zander Therapeutics, Inc. (“Zander) in the amount of $64,400. On January 10, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable January 10, 2020. On January 14, 2019 Zander loaned $2,000 to Regen. The loan bears simple interest at 10% and is due and payable January 14, 2020. On January 17, 2019 Zander loaned $1,500 to Regen. The loan bears simple interest at 10% and is due and payable January 17, 2020. On April 11, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable April 11, 2020. On April 30, 2019 Zander loaned $20,000 to Regen. The loan bears simple interest at 10% and is due and payable April 30, 2020. On May 3, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable May 3, 2020. On May 9, 2019 Zander loaned $400 to Regen. The loan bears simple interest at 10% and is due and payable May 9, 2020. On May 29, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable May 29, 2020. On May 31, 2019 Zander loaned $6,000 to Regen. The loan bears simple interest at 10% and is due and payable May 31, 2020. On June 6, 2019 Zander loaned $4,000 to Regen. The loan bears simple interest at 10% and is due and payable June 6, 2020. On June 14, 2019 Zander loaned $3,000 to Regen. The loan bears simple interest at 10% and is due and payable June 14, 2020. On July 1, 2019 Zander loaned $6,000 to Regen. The loan bears simple interest at 10% and is due and payable July 1, 2020. On July 3, 2019 Zander loaned $6,000 to Regen of which $1,500 remained outstanding as of September 30, 2019. The loan bears simple interest at 10% and is due and payable July 3, 2020. As of September 20, 2019 the Company is indebted to BST Partners in the amount of $24,000. On July 19,2019 BST Partners loaned $2,000 to Regen. The loan bears simple interest at 10% and is due and payable July 19, 2020. On September 5, 2019 BST Partners loaned $6,000 to Regen. The loan bears simple interest at 10% and is due and payable September 5, 2020. On September 13, 2019 BST Partners loaned $10,000 to Regen. The loan bears simple interest at 10% and is due and payable September 13, 2020. On September 30, 2019 BST Partners loaned $6,000 to Regen. The loan bears simple interest at 10% and is due and payable September 30, 2020. During the year ended September 30, 2019 Zander and Regen were under common control. David Koos served as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Todd S. Caven served as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos and Caven also served as a Director of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
Convertible Notes Payable	Sep. 30, 2019
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 5. CONVERTIBLE NOTES PAYABLE On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property The issuance of the Note amounted in a beneficial conversion feature of $42,600 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $ 0. As of September 30, 2019 $100,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2019 is $0. On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or ten cents per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property The issuance of the Note amounted in a beneficial conversion feature of $9,900 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $0. As of September 30, 2019 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2019 is $0. On September 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $ 0. As of September 30, 2019 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2019 is 0. On September 20, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than three (3) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $ 0. As of September 30, 2019 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2019 is 0. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $0. As of September 30, 2019 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2019 is 0. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $ 0 As of September 30, 2019 $50,000 of the principal amount of the Note remains outstanding. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.0125 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $0. As of September 30, 2019 $50,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2019 is 0. On December 22, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $40,000 for consideration consisting of $40,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is one year from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $0.01 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. The issuance of the Note amounted in a beneficial conversion feature of $40,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $ 0. As of September 30, 2019 $40,000 of the principal amount of the Note remains outstanding. The amount by which the Note’s as converted value exceeds the principal amount as of September 30, 2019 is 0. On March 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $75,000 for consideration consisting of $75,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 1, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of September 30 , 2019 $75,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The issuance of the Note amounted in a discount of $75,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $ 11,359. On March 9, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 9, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.025 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of September 30, 2019 $25,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $125,000 was recognized by the Company as of September 30, 2019. The issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $3,968 The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of September 30, 2019 $50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $181,818 was recognized by the Company as of September 30, 2019. The issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $7,211 On March 31, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 31, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of September 30, 2019 $50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $181,818 was recognized by the Company as of September 30, 2019. The issuance of the Note amounted in a discount of $50,000 which is amortized under the Interest Method over the life of the Note. As of September 30, 2019 the unamortized discount on the convertible note outstanding is $9,352. On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.05 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of September 30, 2019 $25,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $90,909 was recognized by the Company as of September 30, 2019. The issuance of the Note amounted in a discount of $25,000 which is amortized under the Interest Method over the life of the Note. As of September 30,, 2019 the unamortized discount on the convertible note outstanding is $4,676. On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020. All or part of the principal is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.0125 per common share. The Company shall have the right, exercisable on not less than ten (10) Trading Day

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 6. INCOME TAXES As of September 30, 2018 Deferred tax assets: Net operating tax carry forwards $ 4,197,657 Other -0- Gross deferred tax assets 4,199,598 Valuation allowance (4,199,598 ) Net deferred tax assets $ -0- As of September 30 2019 the Company has a Deferred Tax Asset of $4,199,598 completely attributable to net operating loss carry forwards of approximately $19,998,086. The amount and availability of any net operating loss carryforward will be subject to the limitations set forth in the Internal Revenue Code. Such factors as the number of shares ultimately issued within a three-year look-back period; whether there is a deemed more than 50% change in control; the applicable long-term tax exempt bond rate; continuity of historical business; and subsequent income of the Company all enter into the annual computation of allowable annual utilization of any net operating loss carryforward. Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. A corporation is considered to undergo “an ownership change” if, as a result of changes in the stock ownership by “5-percent shareholders” or as a result of certain reorganizations, the percentage of the corporation’s stock owned by those 5-percent shareholders increases by more than 50 percentage points over the lowest percentage of stock owned by those shareholders at any time during the prior three-year testing period. Five-percent shareholders are persons who hold 5% or more of the stock of a corporation at any time during the testing period as well as certain groups of shareholders (based typically on whether they acquired their shares in a single offering or exchange transaction) who are not individually 5-percent shareholders. As the Company will require cash infusions in order to implement its business plan, and as it is probable, although not guaranteed, that such funding needs may be met through the sale of equity securities to “5-percent shareholders”, the Company recognized a valuation allowance equal to the deferred Tax Asset and the Company recorded a valuation allowance reducing all deferred tax assets to 0.

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Sep. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7. RELATED PARTY TRANSACTIONS During the fiscal year ended September 30, 2019 the Company utilized approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by BST Partners on a month to month basis beginning November 1 2018. BST Partners is controlled by David R. Koos who also serves as the Chief Executive Officer of the Company. The sublease was on a month to month basis and rent payable to BST Partners by Regen Biopharma Inc equaled $5,000 per month. On January 20, 2020 the Company and BST Partners Inc. agreed that the month to month sublease by and between the Company and BST Partners, Inc. whereby the Company subleased office space from BST Partners, Inc.at 4700 Spring Street, St 304, La Mesa, California 91942 shall terminate as of 1pm Pacific Standard Time on January 22, 2020. On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company. Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement. The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander. Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000). The Agreement may be terminated by The Company: If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party. On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto. Zander and Regen are under common control. David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Harry Lander serves as President and Chief Scientific Officer of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. Todd S. Caven serves as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos, Lander and Caven also serve as Directors of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications. On July 11, 2018 the Company issued a Convertible Note (“Note”) in the face amount of $11,500 to an entity controlled by the Company’s Chief Financial Officer for consideration consisting of $11,500 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May 4, 2021. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $0.01 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $0.01 per share. In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note. As of September 30, 2019 $11,500 of the principal amount of the Note remains outstanding. On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date. Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen. As of 30, 2019, $10,000 of the principal amount of the Note remains outstanding. Zander and Regen are under common control. David Koos serves as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Todd S. Caven serves as CFO of Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos, Caven also serves as Directors of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications. As of September 30, 2019 the Company is indebted to David R. Koos in the amount of $227. $227 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum. As of September 30, 2019 Regen Biopharma Inc. is indebted to Zander Therapeutics, Inc. (“Zander) in the amount of $64,400. On January 10, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable January 10, 2020. On January 14, 2019 Zander loaned $2,000 to Regen. The loan bears simple interest at 10% and is due and payable January 14, 2020. On January 17, 2019 Zander loaned $1,500 to Regen. The loan bears simple interest at 10% and is due and payable January 17, 2020. On April 11, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable April 11, 2020. On April 30, 2019 Zander loaned $20,000 to Regen. The loan bears simple interest at 10% and is due and payable April 30, 2020. On May 3, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable May 3, 2020. On May 9, 2019 Zander loaned $400 to Regen. The loan bears simple interest at 10% and is due and payable May 9, 2020. On May 29, 2019 Zander loaned $5,000 to Regen. The loan bears simple interest at 10% and is due and payable May 29, 2020. On May 31, 2019 Zander loaned $6,000 to Regen. The loan bears simple interest at 10% and is due and payable May 31, 2020. On June 6, 2019 Zander loaned $4,000 to Regen. The loan bears simple interest at 10% and is due and payable June 6, 2020. On June 14, 2019 Zander loaned $3,000 to Regen. The loan bears simple interest at 10% and is due and payable June 14, 2020. On July 1, 2019 Zander loaned $6,000 to Regen. The loan bears simple interest at 10% and is due and payable July 1, 2020. On July 3, 2019 Zander loaned $6,000 to Regen of which $1,500 remained outstanding as of September 30, 2019. The loan bears simple interest at 10% and is due and payable July 3, 2020. As of September 20, 2019 the Company is indebted to BST Partners in the amount of $24,000. On July 19,2019 BST Partners loaned $2,000 to Regen. The loan bears simple interest at 10% and is due and payable July 19, 2020. On September 5, 2019 BST Partners loaned $6,000 to Regen. The loan bears simple interest at 10% and is due and payable September 5, 2020. On September 13, 2019 BST Partners loaned $10,000 to Regen. The loan bears simple interest at 10% and is due and payable September 13, 2020. On September 30, 2019 BST Partners loaned $6,000 to Regen. The loan bears simple interest at 10% and is due and payable September 30, 2020. During the year ended September 30, 2019 Zander and Regen were under common control. David Koos served as Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Todd S. Caven served as CFO of both Regen BioPharma, Inc. and Zander Therapeutics Inc. Koos and Caven also served as a Director of Zander Therapeutics, Inc. Zander Therapeutics, Inc. is the sole licensee of Regen's NR2F6 intellectual property for veterinary applications. On March 23, 2021 Todd S. Caven resigned from his position as Chairman of the Board of Directors, Chief Executive Officer and any and all other offices he may hold of Regen BioPharma ,Inc. and KCL Therapeutics Inc. As of March 23, 2021 David R. Koos became the sole officer and director of both the registrant and KCL Therapeutics, Inc.

Accounts Receivable, Related Pa

Accounts Receivable, Related Party	12 Months Ended
Accounts Receivable, Related Party	Sep. 30, 2019
Credit Loss [Abstract]
Accounts Receivable, Related Party	NOTE 8. ACCOUNTS RECEIVABLE, RELATED PARTY Accounts Receivable due from Related Party as of September 30, 2019 consists solely of amounts earned by the Company not yet paid resulting from the Company’s license agreement with KCL Therapeutics ( See Note 7) .

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9. COMMITMENTS AND CONTINGENCIES On November 16, 2018 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning November 1, 2018. On January 20, 2020 the Company and BST Partners Inc. agreed that the month to month sublease by and between the Company and BST Partners, Inc. whereby the Company subleased office space from BST Partners, Inc.at 4700 Spring Street, St 304, La Mesa, California 91942 shall terminate as of 1pm Pacific Standard Time on January 22, 2020. BST is controlled by David Koos, Regen Biopharma, Inc.’s Chairman and Chief Executive Officer. On December 13, 2019 a complaint was filed in the Superior Court of California, County of San Diego against Regen Biopharma, Inc. (“Company”) , the Company’s Chairman, Zander Therapeutics Inc (“Zander”), and Does 1-50 by ChemDiv, Inc. (“Plaintiff”) alleging Breach of Contract, Unfair Business Practices under the California Business and Professions Code, and Bad Faith Denial of a Contract ( alleged solely against the Company and DOE defendants) stemming from contract research work performed by the Plaintiff for the Company and contract research performed by the Plaintiff for Zander. The Plaintiff is also seeking a declaration from the court that the Plaintiff retains full and complete ownership, title, use, and all rights without any limits to the work, tangible property, intellectual property, and any other product or by-product of the work performed by Plaintiff for the Company and Zander. The action arises from approximately $1.2 million dollars of unpaid invoices (“Unpaid Invoices”) due and payable to the Plaintiff. The Company believes that no portion of the Unpaid Invoices are due and payable by the Company. The outcome of this legal proceeding may adversely affect the Company’s financial condition and operations and may also result in loss of control by the Company of certain intellectual property controlled by the Company.

Stockholders Equity

Stockholders Equity	12 Months Ended
Stockholders Equity	Sep. 30, 2019
Equity [Abstract]
Stockholders Equity	NOTE 10. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following classes of capital stock as of September 30, 2019: Common stock, $ 0.0001 par value; 4, 800,000,000 shares authorized: 600, 001,406 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 50,000 shares issued and outstanding as of September 30, 2019, 300,000,000 is designated Series A Preferred Stock of which 348,376,230 shares are outstanding as of September 30, 2019 and 300,000,000 is designated Series M Preferred Stock of which 38,000,000 shares are outstanding as of September 30, 2019. The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”). The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Series A Preferred Stock On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”). The Board of Directors of the Company have authorized 300,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board. On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock"). The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

Investment Securities

Investment Securities	12 Months Ended
Investment Securities	Sep. 30, 2019
Accounting Policies [Abstract]
Investment Securities	11. INVESTMENT SECURITIES On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc. On November 29, 2018 the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $13,124. On September 30, 2019 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs: Fair Value of Intellectual Property $ 1,500 Prepaid Expenses 74,298 Due from Employee 1,071 Note Receivable 64,400 Accrued Interest Receivable 20,274 Investment Securities 593,357 Convertible Note Receivable 10,000 Accounts Payable 1,269,041 Notes Payable 500,000 Accrued Expenses Related Parties 89,529 Accrued Expenses 203,037 Enterprise Value 2,826,507 Less: Total Debt (2,061,607 ) Portion of Enterprise Value Attributable to Shareholders 764,900 Fair Value Per Share $ 0.0167 The abovementioned constitute the Company’s sole investment securities as of September 30, 2019 As of September 30, 2019: 470,588 Common Shares of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Gains Net Unrealized Gain or (Loss) realized during the Year ended September 30, 2019 $ 5,741 $ 7,858 $ 2,118 $(50,831) 725,000 Series M Preferred of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Loss Net Unrealized Gain or (Loss) realized during the Year ended September 30, 2019 $ 13,124 $ 12,109 $ (1,104 ) $(1,104)

Stock Transactions

Stock Transactions	12 Months Ended
Stock Transactions	Sep. 30, 2019
Notes to Financial Statements
Stock Transactions	NOTE 12. STOCK TRANSACTIONS Issuance of Common Shares On October 1, 2018 the Company issued 5,128,205 common shares in satisfaction of $30,000 of convertible indebtedness. On October 18, 2018 the Company issued 8,961,988 common shares in satisfaction of $30,650 of convertible indebtedness. On October 23, 2018 the Company issued 2,019,940 common shares in satisfaction of $7,000 of convertible indebtedness and 612 of accrued interest on convertible indebtedness. On October 29, 2018 the Company issued 3,015,618 common shares in satisfaction of $11,000 of convertible indebtedness and 368 of accrued interest on convertible indebtedness. On November 15, 2018 the Company issued 7,100,591 common shares in satisfaction of $30,000 of convertible indebtedness. On November 28, 2018 the Company issued 29,033,181 common shares in satisfaction of $50,716 of convertible indebtedness. On November 28, 2018 the Company issued 286,232 common shares in satisfaction of, $500 in fees On December 19, 2018 the Company issued 5,184,674 common shares in satisfaction of $10,000 of convertible indebtedness and $447 of accrued interest on convertible indebtedness. On December 26, 2018 the Company issued 11,000,000 common shares in satisfaction of $7,710 of convertible indebtedness, $500 in fees and $700 of accrued interest on convertible indebtedness. On January 3, 2019 the Company issued 10585123 common shares in satisfaction of $4607 of convertible indebtedness and $9153 of accrued interest on convertible indebtedness. On January 23, 2019 the Company issued 5774947 common shares in satisfaction of $6770 of convertible indebtedness and $362 of accrued interest on convertible indebtedness. On January 25, 2019 the Company issued 13100000 common shares in satisfaction of $5975 of convertible indebtedness , $500 in fees and $991 of accrued interest on convertible indebtedness. On February 11, 2019 the Company issued 10473668 common shares in satisfaction of $12230 of convertible indebtedness and $704 of accrued interest on convertible indebtedness. On February 15, 2019 the Company issued 13821193 common shares in satisfaction of $15000 of convertible indebtedness and $756 of accrued interest on convertible indebtedness. On February 19, 2019 the Company issued 13790783 common shares in satisfaction of $17500 of convertible indebtedness and $2,220 of accrued interest on convertible indebtedness. On March 1, 2019 the Company issued 8004463 common shares in satisfaction of $8200 of convertible indebtedness and $444 of accrued interest on convertible indebtedness. On March 4, 2019 the Company issued 15000000 common shares in satisfaction of $8756 of convertible indebtedness, $500 in fees and $1543 of accrued interest on convertible indebtedness. On March 19, 2019 the Company issued 28,210,615 common shares in satisfaction of $22,504 of convertible indebtedness and $500 in fees . On March 22, 2019 the Company issued 6309524 common shares in satisfaction of $5000 of convertible indebtedness and $300 of accrued interest on convertible indebtedness. On April 1, 2019 the Company issued 10,000,000 common shares in satisfaction of $3,591 of convertible indebtedness and $708 of accrued interest on convertible indebtedness, and $500 in Fees. On April 2, 2019 the Company issued 12,992,839 common shares in satisfaction of $8,800 of convertible indebtedness and $554 of accrued interest on convertible indebtedness. On April 8, 2019 the Company issued 17,971,064 common shares in satisfaction of $12,100 of convertible indebtedness and $1,917 of accrued interest on convertible indebtedness. On April 9, 2019 the Company issued 11,832,569 common shares in satisfaction of $8,000 of convertible indebtedness and $519 of accrued interest on convertible indebtedness. On April 11, 2019 the Company issued 19,472,820 common shares in satisfaction of $14,600 of convertible indebtedness and $588 of accrued interest on convertible indebtedness. On April 18, 2019 the Company issued 14,824,958 common shares in satisfaction of $10,000 of convertible indebtedness and $673 of accrued interest on convertible indebtedness. On April 29, 2019 the Company issued 22,243,153 common shares in satisfaction of $14,800 of convertible indebtedness and $2549 of accrued interest on convertible indebtedness. On April 30, 2019 the Company issued 10,000,000 common shares in satisfaction of $2,788 of convertible indebtedness and $1,511 of accrued interest on convertible indebtedness, and $500 in Fees. On May 18, 2019 the Company issued 22,000,000 common shares in satisfaction of $7,948 of convertible indebtedness, $500 in fees and $352 of accrued interest on convertible indebtedness. On July 12, 2019 the Company issued 25,870,700 common shares in satisfaction of $2,049 of convertible indebtedness, $500 in fees and $2,883 of accrued interest on convertible indebtedness. On July 31, 2019 the Company issued 27,161,700 common shares in satisfaction of $2,962 of convertible indebtedness, $500 in fees and $611 of accrued interest on convertible indebtedness. On September 19,2019 the Company issued 28,517,000 common shares in satisfaction of $2,900 of convertible indebtedness, $500 in fees and $876 of accrued interest on convertible indebtedness. Issuance of Series A Preferred Shares On November 20, 2019 the Company issued 3,656,020 of Series A Preferred shares in satisfaction of $5,465 of convertible indebtedness. On January 9, 2019 the Company issued 10,000,000 Series A Preferred shares to a consultant as consideration for services. On June 27, 2019 the Company issued 194,285, 714 shares of the Series A Preferred stock of Regen to Zander Therapeutics in satisfaction of $340,000 of convertible indebtedness. Issuance of common shares of KCL Therapeutics, Inc. On January 23, 2019 Dr. Harry Lander and the KCL Therapeutics, Inc (“KCL”) entered into an agreement (“Agreement”) whereby Dr. Lander agreed to provide services as KCL’s Senior Scientific Consultant. Pursuant to the Agreement, Dr. Lander will assist KCL with its development of therapies involving checkpoint NR2F6 therapies. The term of the Agreement is from January 25, 2019 to January 24, 2022 and may be extended by mutual consent. Sole consideration to Dr. Lander for services to be provided pursuant to the Agreement shall be the issuance to Dr. Lander by KCL of 5,000,000 shares of KCL’s common stock. On February 13, 2019 Dr. Lander was issued 5,000,000 of the common shares of KCL. On February 13, 2019 David Koos, the Chairman and Chief Executive Officer of both Regen and KCL, was issued 5,000,000 of the common shares of KCL as consideration for services. On February 13, 2019 Todd Caven, the then Chief Financial Officer of both Regen and KCL, was issued 5,000,000 of the common shares of KCL as consideration for services. On August 13, 2019 David Koos, the Chairman and Chief Executive Officer of Regen Biopharma, Inc. (“Company”) returned 5,000,000 common shares of KCL Therapeutics, Inc. (“KCL”) to KCL for cancellation. On August 13, 2019 Todd Caven , the then Chief Financial Officer of the Company returned 5,000,000 common shares of KCL to KCL for cancellation. On August 14th, 2019 5,000,000 common shares of KCL Therapeutics, Inc. (“KCL”) owned by Dr. Harry Lander were cancelled by KCL pursuant to a request from Dr. Lander received by KCL on August 13th 2019.

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 13. SUBSEQUENT EVENTS Issuance of Common Shares: October 29, 2019 the Company issued 24,253,038 common shares in satisfaction of $10,000 of convertible indebtedness and $1,035 of accrued interest on convertible indebtedness. On October 29, 2019 the Company issued 19,475,615 common shares in satisfaction of $4,907of convertible indebtedness and $1,422 of accrued interest on convertible indebtedness. On November 5, 2019 the Company issued 29,219,194 common shares in satisfaction of $9,000 of convertible indebtedness and $1,518 of accrued interest on convertible indebtedness. On November 5, 2019 the Company issued 28,000,000 common shares in satisfaction of $5,775 of convertible indebtedness and $2,625 of accrued interest on convertible indebtedness. On November 5, 2019 the Company issued 28,000,000 common shares in satisfaction of $5,775 of convertible indebtedness and $2,625 of accrued interest on convertible indebtedness. On November 5, 2019 the Company issued 30,555,555 common shares in satisfaction of $11,000 of convertible indebtedness . On November 27, 2019 the Company issued 36,500,000 common shares in satisfaction of 2785 accrued interest on convertible indebtedness and $500 in fees. On December 3, 2019 the Company issued 36,114,111 common shares in satisfaction of $5,500 of convertible indebtedness and $1,000 accrued interest on convertible indebtedness . On December 4, 2019 the Company issued 36,542,564 common shares in satisfaction of $6,090 of convertible indebtedness and $1,035 accrued interest on convertible indebtedness . On December 5, 2019 the Company issued 41,922,222 common shares in satisfaction of $7,456 of convertible indebtedness . On December 6, 2019 the Company issued 41,923,556 common shares in satisfaction of $907 of convertible indebtedness and $2,365 accrued interest on convertible indebtedness . On December 10, 2019 the Company issued 49,729,272 common shares in satisfaction of $5,878 of convertible indebtedness . On December 13, 2019 the Company issued 52,214,500 common shares in satisfaction of $2,266 of convertible indebtedness and $366 of accrued interest on convertible indebtedness and $500 in fees. On December 13, 2019 the Company issued 52,200,000 common shares in satisfaction of $3,132 of convertible indebtedness. On December 16, 2019 the Company issued 49,759,153 common shares in satisfaction of $5,470 of convertible indebtedness and $988 of accrued interest on convertible indebtedness. On December 19, 2019 the Company issued 42,000,000 common shares in satisfaction of $3,280 of convertible indebtedness On December 20, 2019 the Company issued 59,940,000 common shares in satisfaction of $3,280 of convertible indebtedness and $616 of accrued interest on convertible indebtedness. On December 20, 2019 the Company issued 59,900,000 common shares in satisfaction of $3,594 of convertible indebtedness. On December 23, 2019 the Company issued 59,907,667 common shares in satisfaction of $942 of convertible indebtedness, $354 of accrued interest on convertible indebtedness and $500 in fees. On January 2, 2020 the Company issued 69,685,185 common shares in satisfaction of $3,763 of convertible indebtedness. On January 2, 2020 the Company issued 70,793,000 common shares in satisfaction of $1,104 of convertible indebtedness , 524 of accrued interest on convertible indebtedness and $500 in fees. On January 23, 2020 the Company issued 42,035,947 common shares in satisfaction of $202 of convertible indebtedness , $558 of accrued interest on convertible indebtedness and $500 in fees. On October 28, 2020 the Company issued 80,065,846 common shares in satisfaction of $3,752 of convertible indebtedness and $1,452 of accrued interest on convertible indebtedness. On November 6, 2020 the Company issued 83,934,153 common shares in satisfaction of $3,900 of convertible indebtedness and $1,555 of accrued interest on convertible indebtedness. On December 11, 2020 the Company issued 87,020,000 common shares in satisfaction of $7,300 of convertible indebtedness and $3,142 of accrued interest on convertible indebtedness. On December 16, 2020 the Company issued 6,437,153 common shares in satisfaction of $852 of convertible indebtedness , $429 of accrued interest on convertible indebtedness and $160 in fees.. On December 16, 2020 the Company issued 88,158,923 common shares in satisfaction of $4,030 of convertible indebtedness and $1,700 of accrued interest on convertible indebtedness. On December 17, 2020 the Company issued 83,216,917 common shares in satisfaction of $8,200 of convertible indebtedness and $1,786 of accrued interest on convertible indebtedness. On December 23, 2020 the Company issued 108,444,444 common shares in satisfaction of $16,000 of convertible indebtedness and $3,250 of accrued interest on convertible indebtedness. On December 31, 2020 the Company issued 117,837,384 common shares in satisfaction of $5,330 of convertible indebtedness and $2,329 of accrued interest on convertible indebtedness. On January 28, 2021 the Company issued 85,900,000 common shares in satisfaction of $5,154 of convertible indebtedness. On February 23, 2021 the Company issued 88,000,000 common shares in satisfaction of $4,400 of accrued interest on convertible indebtedness. On February 24, 2021 the Company issued 82,759,286 common shares in satisfaction of $30,000 of convertible indebtedness and $4,758 of accrued interest on convertible indebtedness. On March 2, 2021 the Company issued 119,269,538 common shares in satisfaction of $5,260 of convertible indebtedness and $2,492 of accrued interest on convertible indebtedness. On March 18, 2021 the Company issued 70,000,000 common shares in satisfaction of $3,415 of convertible indebtedness and $84 of accrued interest on convertible indebtedness. On March 31, 2021 the Company issued 40,000,000 common shares in satisfaction of $1926 of convertible indebtedness and $74 of accrued interest on convertible indebtedness. On April 12, 2021 the Company issued 85,000,000 common shares in satisfaction of $3111 of convertible indebtedness and $49 of accrued interest on convertible indebtedness. On April 13, 2021 the Company issued 83,636,833 common shares in satisfaction of $3,511 of convertible indebtedness and $1508 of accrued interest on convertible indebtedness. On April 13, 2021 the Company issued 32,968,042 common shares in satisfaction of $19,000 of convertible indebtedness and $4736 of accrued interest on convertible indebtedness. On April 15, 2021 the Company issued 146,452,000 common shares in satisfaction of $1,416 of convertible indebtedness and $680 of accrued interest on convertible indebtedness. On April 15, 2021 the Company issued 49482000 common shares in satisfaction of $2288 of convertible indebtedness and $680 of accrued interest on convertible indebtedness. On April 16, 2021 the Company issued 70,755,885 common shares in satisfaction of $47,000 of convertible indebtedness and $8,189 of accrued interest on convertible indebtedness. On April 16, 2021 the Company issued 90,311,411 common shares in satisfaction of $4,238 of convertible indebtedness and $17 of accrued interest on convertible indebtedness. On April 21, 2021 the Company issued 163,814,000 common shares in satisfaction of $7564 of convertible indebtedness and $2,264 of accrued interest on convertible indebtedness. On April 28, 2021 the Company issued 28,784,167 common shares in satisfaction of $22,000 of convertible indebtedness and $3,905 of accrued interest on convertible indebtedness. On May 3, 2021 the Company issued 33,012,555 common shares in satisfaction of $1,416 of convertible indebtedness and $729 of accrued interest on convertible indebtedness. On May 5, 2021 the Company issued 27,753,016 common shares in satisfaction of $1,187 of convertible indebtedness and $616 of accrued interest on convertible indebtedness. Issuance of Series A Preferred Shares: On May 12, 2020 the Company issued 5,238,875 Series A Preferred shares in satisfaction of $3,000 of convertible indebtedness and $1,426 of accrued interest on convertible indebtedness. On July 1, 2020 the Company issued 11,603,784 Series A Preferred shares in satisfaction of $5,000 of convertible indebtedness and $2,542 of accrued interest on convertible indebtedness. On August 7, 2020 the Company issued 16,549,800 Series A Preferred shares in satisfaction of $7,000 of convertible indebtedness and $3,757 of accrued interest on convertible indebtedness. On December 17, 2020 the Company issued 32,379,169 Series A Preferred shares in satisfaction of $13,000 of convertible indebtedness and $8,046 of accrued interest on convertible indebtedness. Issuance of Series M Preferred Shares: On November 15, 2019 the Company issued 4,000,000 Series M Preferred shares as consideration for services. On November 18, 2019 the Company issued 2,000,000 Series M Preferred shares as consideration for services. Issuance of Series NC Preferred Shares On April 13, 2021 the Company issued 10,000 Series NC Preferred shares to its Chief Executive Officer as consideration for services. Certificate of Designations On March 26, 2021 Regen Biopharma, Inc. ( “Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock (hereinafter referred to as "Series NC Preferred Stock"). The Board of Directors of Regen have authorized 20,000 shares of the Series NC Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series NC Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series NC Preferred Stock owned by such holder times 500,000. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series NC Preferred Stock shall vote as a single class on all matters submitted to the stockholders. The holders of Series NC Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen. Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure; During the Registrant's most two most recent fiscal years there were no disagreements with AMC Auditing (“AMC”), the Company’s independent registered public accounting firm from October 19, 2016 to April 8, 2019, whether or not resolved, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to AMC’s satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its report on the Registrant's financial statements. During the Registrant's most two most recent fiscal years there were no disagreements with A Prager Metis CPA’s LLP (“Prager), the Company’s independent registered public accounting firm from April 8, 2019 to July 24, 2019, whether or not resolved, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Prager’s satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its report on the Registrant's financial statements. During the Registrant's most two most recent fiscal years there were no disagreements with BF Borgers CPA PC (“Borgers”), the Company’s independent registered public accounting firm from July 24, 2019 to the present, whether or not resolved, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Borgers’ satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its report on the Registrant's financial statements.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
PRINCIPLES OF CONSOLIDATION	B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Black Scoles pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of June 30, 2019 utilized the following inputs: Risk Free Interest Rate 1.75 % Expected Term 0.042 – 1.59 Yrs Expected Volatility 207.11 – 273.20 % Expected Dividends
INCOME TAXES	C. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2019 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	D. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.
ADVERTISING	E. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the years ended September 30, 2019 and 2018.
NOTES RECEIVABLE	F. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any.
REVENUE RECOGNITION	G. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
INTEREST RECEIVABLE	H. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Schedule of Derivative Liability	The Black Scoles pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of June 30, 2019 utilized the following inputs: Risk Free Interest Rate 1.75 % Expected Term 0.042 – 1.59 Yrs Expected Volatility 207.11 – 273.20 % Expected Dividends

Notes Payable, Related Party (T

Notes Payable, Related Party (Tables)	12 Months Ended
Notes Payable, Related Party (Tables)	Sep. 30, 2019
Debt Disclosure [Abstract]
Notes Payable Related Party	As of September 30, 2019 David Koos $ 227 Zander Therapeutics, Inc. 64,400 BST Partners 24,000 Total: $ 88,627

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Deferred tax assets	As of September 30, 2018 Deferred tax assets: Net operating tax carry forwards $ 4,197,657 Other -0- Gross deferred tax assets 4,199,598 Valuation allowance (4,199,598 ) Net deferred tax assets $ -0-

Investment Securities (Tables)

Investment Securities (Tables)	12 Months Ended
Investment Securities (Tables)	Sep. 30, 2019
Accounting Policies [Abstract]
Dividend Income	On September 30, 2019 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs: Fair Value of Intellectual Property $ 1,500 Prepaid Expenses 74,298 Due from Employee 1,071 Note Receivable 64,400 Accrued Interest Receivable 20,274 Investment Securities 593,357 Convertible Note Receivable 10,000 Accounts Payable 1,269,041 Notes Payable 500,000 Accrued Expenses Related Parties 89,529 Accrued Expenses 203,037 Enterprise Value 2,826,507 Less: Total Debt (2,061,607 ) Portion of Enterprise Value Attributable to Shareholders 764,900 Fair Value Per Share $ 0.0167
Comprehensive Income	As of September 30, 2019: 470,588 Common Shares of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Gains Net Unrealized Gain or (Loss) realized during the Year ended September 30, 2019 $ 5,741 $ 7,858 $ 2,118 $(50,831) 725,000 Series M Preferred of Zander Therapeutics, Inc. Basis Fair Value Total Unrealized Loss Net Unrealized Gain or (Loss) realized during the Year ended September 30, 2019 $ 13,124 $ 12,109 $ (1,104 ) $(1,104)

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies (Details)	12 Months Ended
	Sep. 30, 2019
Risk Free Interest Rate	1.75%
Expected Volatility, Minimum	207.11%
Expected Volatility, Maximum	273.20%
Expected Dividends	0.00%
Minimum [Member]
Expected Term	5 months 1 day
Maximum [Member]
Expected Term	1 year 7 months 2 days

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Accounting Policies [Abstract]
Advertising expenses	$ 0	$ 0
Valuation allowance	100.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative)	83 Months Ended
Going Concern (Details Narrative)	Sep. 30, 2019USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss since inception	$ (19,998,086)

Notes Payable, Related Party (D

Notes Payable, Related Party (Details)	Sep. 30, 2019USD ($)
Notes Payable	$ 88,627
David Koos
Notes Payable	227
Zander Therapeutics
Notes Payable	64,400
BST Partners
Notes Payable	$ 24,000

Notes Payable, Related Party _2

Notes Payable, Related Party (Details Narrative) - USD ($)	Sep. 13, 2019	Sep. 05, 2019	Jul. 03, 2019	Jul. 02, 2019	Jun. 14, 2019	Jun. 06, 2019	May 09, 2019	May 03, 2019	Apr. 11, 2019	Jan. 14, 2019	Jan. 10, 2019	Sep. 30, 2019	Jul. 19, 2019	May 31, 2019	May 29, 2019	Apr. 30, 2019	Jan. 17, 2019	Sep. 30, 2019	Jun. 30, 2019	Jan. 07, 2019
David Koos
Note payable												$ 227						$ 227	$ 227
Interest rate per annum																		15.00%
Entest Biomedical, Inc
Interest rate per annum																		10.00%
BST Partners
Loan	$ 10,000	$ 6,000										$ 6,000	$ 2,000					$ 6,000
Interest rate	10.00%	10.00%										10.00%	10.00%
Due date	Sep. 13, 2020	Sep. 5, 2020										Sep. 30, 2020	Jul. 19, 2020
Indebted Amount												$ 24,000						24,000
Zander Therapeutics
Loan			$ 6,000	$ 6,000	$ 3,000	$ 4,000	$ 400	$ 5,000	$ 5,000	$ 2,000	$ 5,000			$ 6,000	$ 5,000	$ 20,000	$ 1,500			$ 6,000
Interest rate			10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%			10.00%	10.00%	10.00%	10.00%
Due date			Jul. 3, 2020	Jul. 1, 2020	Jun. 14, 2020	Jun. 6, 2020	May 9, 2020	May 3, 2020	Apr. 11, 2020	Jan. 14, 2020	Jan. 10, 2020			May 31, 2020	May 29, 2020	Apr. 30, 2020	Jan. 17, 2020
Indebted Amount												$ 64,400						$ 64,400

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	12 Months Ended
Convertible Notes Payable (Details Narrative)	Sep. 30, 2019USD ($)shares
Convertible Note; December 22, 2016
Convertible note issued and outstanding	$ 40,000
Convertible note, interest rate	10.00%
Unamortized discount	$ 0
Outstanding balance	40,000
Cash issued for convertible note	40,000
Convertible Note; March 8, 2016
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	8.00%
Maturity Date	Mar. 8, 2019
Beneficial conversion feature	$ 42,600
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	100,000
Cash issued for convertible note	100,000
Convertible Note; April 6, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	8.00%
Maturity Date	Apr. 6, 2019
Beneficial conversion feature	$ 9,900
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	50,000
Convertible Note; September 8, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 8, 2017
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	50,000
Convertible Note; September 20, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 20, 2017
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	50,000
Convertible Note; October 31, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 31, 2018
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	50,000
Convertible Note #2; October 31, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 31, 2018
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	50,000
Convertible Note #3; October 31, 2016
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 31, 2018
Beneficial conversion feature	$ 50,000
Unamortized discount	0
Converted value that exceeds the principal amount	0
Outstanding balance	50,000
Cash issued for convertible note	$ 50,000
Convertible Note; December 22, 2016
Maturity Date	Dec. 22, 2017
Beneficial conversion feature	$ 40,000
Converted value that exceeds the principal amount	0
Convertible Note; March 1, 2017
Convertible note issued and outstanding	$ 75,000
Convertible note, interest rate	10.00%
Maturity Date	Mar. 1, 2020
Unamortized discount	$ 11,359
Outstanding balance	75,000
Derivative Liability	272,727
Cash issued for convertible note	75,000
Convertible Note; March 9, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Mar. 9, 2020
Unamortized discount	$ 3,968
Outstanding balance	25,000
Derivative Liability	125,000
Cash issued for convertible note	25,000
Convertible Note; March 13, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Feb. 24, 2020
Unamortized discount	$ 7,211
Outstanding balance	50,000
Derivative Liability	181,818
Cash issued for convertible note	25,000
Convertible Note: March 31, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Mar. 31, 2020
Unamortized discount	$ 9,352
Outstanding balance	50,000
Derivative Liability	181,818
Cash issued for convertible note	50,000
Convertible Note; April 19, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Apr. 19, 2020
Unamortized discount	$ 4,676
Outstanding balance	25,000
Derivative Liability	90,909
Cash issued for convertible note	25,000
Convertible Note #2; April 19, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Apr. 19, 2020
Unamortized discount	$ 9,352
Outstanding balance	50,000
Derivative Liability	181,818
Cash issued for convertible note	50,000
Convertible Note; May 5, 2017
Convertible note issued and outstanding	$ 200,000
Convertible note, interest rate	10.00%
Maturity Date	May 5, 2020
Unamortized discount	$ 40,328
Outstanding balance	200,000
Derivative Liability	727,273
Cash issued for convertible note	200,000
Convertible Note; May 10, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	May 9, 2020
Unamortized discount	$ 18,630
Outstanding balance	100,000
Derivative Liability	363,636
Cash issued for convertible note	100,000
Convertible Note; May 19, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	May 19, 2020
Unamortized discount	$ 9,352
Outstanding balance	50,000
Derivative Liability	181,818
Cash issued for convertible note	50,000
Convertible Note; June 26, 2017
Convertible note issued and outstanding	$ 150,000
Convertible note, interest rate	10.00%
Maturity Date	Jun. 16, 2020
Unamortized discount	$ 36,325
Outstanding balance	150,000
Derivative Liability	545,455
Cash issued for convertible note	$ 150,000
Number of shares returned \| shares	3,976,852
Convertible Note; July 24, 2017
Convertible note issued and outstanding	$ 60,000
Convertible note, interest rate	10.00%
Maturity Date	Jul. 24, 2020
Unamortized discount	$ 16,423
Outstanding balance	60,000
Derivative Liability	218,182
Cash issued for convertible note	60,000
Convertible Note; September 7, 2017
Convertible note issued and outstanding	$ 40,000
Convertible note, interest rate	8.00%
Maturity Date	Sep. 7, 2018
Unamortized discount	$ 0
Outstanding balance	7,000
Derivative Liability	61,538
Cash issued for convertible note	38,000
Convertible Note; August 29, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Aug. 29, 2020
Unamortized discount	$ 7,664
Outstanding balance	25,000
Derivative Liability	90,909
Cash issued for convertible note	25,000
Convertible Note; September 22, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 21, 2020
Unamortized discount	$ 16,392
Outstanding balance	50,000
Derivative Liability	181,818
Cash issued for convertible note	50,000
Convertible Note; #2 September 22, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 22, 2020
Unamortized discount	$ 32,846
Outstanding balance	100,000
Derivative Liability	363,636
Cash issued for convertible note	100,000
Convertible Note; September 25, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 25, 2020
Unamortized discount	$ 16,560
Outstanding balance	50,000
Derivative Liability	181,818
Cash issued for convertible note	50,000
Convertible Note; October 3, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 3, 2020
Unamortized discount	$ 17,518
Outstanding balance	50,000
Derivative Liability	181,818
Cash issued for convertible note	50,000
Convertible Note; October 4, 2017
Convertible note issued and outstanding	$ 40,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 4, 2020
Unamortized discount	$ 14,051
Outstanding balance	40,000
Derivative Liability	145,454
Cash issued for convertible note	40,000
Convertible Note; October 16, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 9, 2020
Unamortized discount	$ 36,222
Outstanding balance	100,000
Derivative Liability	363,636
Cash issued for convertible note	100,000
Convertible Note; November 01, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Nov. 1, 2020
Unamortized discount	$ 9,420
Outstanding balance	25,000
Derivative Liability	90,909
Cash issued for convertible note	25,000
Convertible Note; #2 November 1, 2017
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Nov. 1, 2020
Unamortized discount	$ 9,420
Outstanding balance	25,000
Derivative Liability	90,909
Cash issued for convertible note	25,000
Convertible Note; October 9, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 9, 2020
Unamortized discount	$ 18,630
Outstanding balance	100,000
Derivative Liability	363,636
Cash issued for convertible note	100,000
Convertible Note; December 15, 2017
Convertible note issued and outstanding	$ 35,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 15, 2020
Unamortized discount	$ 14,593
Outstanding balance	35,000
Derivative Liability	127,273
Cash issued for convertible note	35,000
Convertible Note; December 20, 2017
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 20, 2020
Unamortized discount	$ 42,153
Outstanding balance	100,000
Derivative Liability	363,636
Cash issued for convertible note	100,000
Convertible Note #2; December 20, 2017
Convertible note issued and outstanding	$ 115,000
Convertible note, interest rate	8.00%
Maturity Date	Dec. 6, 2018
Unamortized discount	$ 0
Outstanding balance	115,000
Derivative Liability	7,077
Cash issued for convertible note	100,000
Original Issue Discount	1,750
Convertible Note; December 06, 2017
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 6, 2020
Unamortized discount	$ 20,437
Outstanding balance	50,000
Derivative Liability	181,818
Cash issued for convertible note	50,000
Convertible Note; January 24, 2018
Convertible note issued and outstanding	$ 25,000
Convertible note, interest rate	10.00%
Maturity Date	Dec. 6, 2020
Unamortized discount	$ 10,350
Outstanding balance	25,000
Derivative Liability	90,909
Cash issued for convertible note	25,000
Convertible Note; February 28, 2018
Convertible note issued and outstanding	$ 100,000
Convertible note, interest rate	10.00%
Maturity Date	Feb. 28, 2021
Unamortized discount	$ 47,901
Outstanding balance	100,000
Derivative Liability	363,636
Cash issued for convertible note	$ 100,000
Convertible Note; February 26, 2018
Maturity Date	Feb. 26, 2019
Convertible Note; May 18, 2018
Convertible note issued and outstanding	$ 114,000
Convertible note, interest rate	10.00%
Maturity Date	Feb. 18, 2019
Unamortized discount	$ 0
Outstanding balance	114,000
Derivative Liability	176,428
Cash issued for convertible note	100,000
Original Issue Discount	14,000
Convertible Note; July 11, 2018
Convertible note issued and outstanding	$ 11,500
Convertible note, interest rate	10.00%
Maturity Date	May 4, 2021
Unamortized discount	$ 6,521
Outstanding balance	11,500
Derivative Liability	41,818
Cash issued for convertible note	$ 11,500
Convertible Note; August 14, 2018
Maturity Date	Aug. 13, 2019
Convertible Note; September 30, 2018
Convertible note issued and outstanding	$ 350,000
Convertible note, interest rate	10.00%
Maturity Date	Sep. 30, 2020
Beneficial conversion feature	$ 350,000
Unamortized discount	350,000
Converted value that exceeds the principal amount	6,666
Outstanding balance	350,000
Cash issued for convertible note	350,000
Convertible Note; October 3, 2018
Convertible note issued and outstanding	$ 63,000
Convertible note, interest rate	8.00%
Maturity Date	Oct. 3, 2019
Unamortized discount	$ 15,117
Outstanding balance	63,000
Derivative Liability	93,076
Cash issued for convertible note	60,000
Convertible Note; October 10, 2018
Convertible note issued and outstanding	$ 75,000
Convertible note, interest rate	10.00%
Maturity Date	Oct. 11, 2019
Unamortized discount	$ 2,459
Outstanding balance	75,000
Derivative Liability	178,571
Cash issued for convertible note	71,250
Convertible Note; January 22, 2019
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	10.00%
Maturity Date	Jan. 22, 2020
Unamortized discount	$ 22,045
Outstanding balance	50,000
Derivative Liability	119,047
Cash issued for convertible note	47,500
Convertible Note; July 19, 2019
Convertible note issued and outstanding	$ 100,000
Maturity Date	Jul. 19, 2020
Unamortized discount	$ 80,054
Outstanding balance	100,000
Derivative Liability	151,515
Cash issued for convertible note	95,000
Convertible Note #2; July 19, 2019
Convertible note issued and outstanding	$ 20,331
Maturity Date	Jul. 19, 2019
Unamortized discount	$ 16,275
Outstanding balance	20,331
Derivative Liability	28,434
Cash issued for convertible note	18,831
Convertible Note #3; July 19, 2019
Convertible note issued and outstanding	$ 14,819
Maturity Date	Jul. 19, 2019
Unamortized discount	$ 14,780
Outstanding balance	14,819
Derivative Liability	22,453
Cash issued for convertible note	13,319
Convertible Note; February 15, 2019
Convertible note issued and outstanding	$ 50,000
Convertible note, interest rate	60.00%
Unamortized discount	$ 19,041
Outstanding balance	50,000
Derivative Liability	104,166
Cash issued for convertible note	$ 47,500

Income Taxes (Details)

Income Taxes (Details)	Sep. 30, 2019USD ($)
Deferred tax assets:
Net operating tax carry forwards	$ 4,197,657
Other	0
Gross deferred tax assets	4,199,598
Valuation allowance	(4,199,598)
Net deferred tax assets	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	Sep. 30, 2019USD ($)
Income Tax Disclosure [Abstract]
Deferred Tax Asset	$ 4,199,598
Net operating loss carry forwards	$ 19,998,086

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Sep. 13, 2019	Sep. 05, 2019	Jul. 03, 2019	Jul. 02, 2019	Jun. 14, 2019	Jun. 06, 2019	May 09, 2019	May 03, 2019	Apr. 11, 2019	Jan. 14, 2019	Jan. 10, 2019	Sep. 30, 2019	Jul. 19, 2019	May 31, 2019	May 29, 2019	Apr. 30, 2019	Jan. 17, 2019	Sep. 30, 2019	Jun. 30, 2019	Jan. 07, 2019
Notes Payable, Total amount												$ 88,627						$ 88,627
Zander Therapeutics
Loan			$ 6,000	$ 6,000	$ 3,000	$ 4,000	$ 400	$ 5,000	$ 5,000	$ 2,000	$ 5,000			$ 6,000	$ 5,000	$ 20,000	$ 1,500			$ 6,000
Interest rate			10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%	10.00%			10.00%	10.00%	10.00%	10.00%
Due date			Jul. 3, 2020	Jul. 1, 2020	Jun. 14, 2020	Jun. 6, 2020	May 9, 2020	May 3, 2020	Apr. 11, 2020	Jan. 14, 2020	Jan. 10, 2020			May 31, 2020	May 29, 2020	Apr. 30, 2020	Jan. 17, 2020
BST Partners
Notes Payable, Total amount												24,000						24,000
Loan	$ 10,000	$ 6,000										$ 6,000	$ 2,000					6,000
Interest rate	10.00%	10.00%										10.00%	10.00%
Due date	Sep. 13, 2020	Sep. 5, 2020										Sep. 30, 2020	Jul. 19, 2020
David Koos
Notes Payable, Total amount												$ 227						227
Note payable												227						227	$ 227
Convertible Note; September 30, 2018
Convertible note issued and outstanding												$ 350,000						$ 350,000
Convertible note, interest rate												10.00%						10.00%
Maturity Date																		Sep. 30, 2020
Outstanding balance												$ 350,000						$ 350,000
Convertible Note; July 11, 2018
Convertible note issued and outstanding												$ 11,500						$ 11,500
Convertible note, interest rate												10.00%						10.00%
Maturity Date																		May 4, 2021
Outstanding balance												$ 11,500						$ 11,500
Zander Therapeutics
Notes Payable, Total amount												$ 64,400						$ 64,400

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	12 Months Ended
Commitments and Contingencies (Details Narrative)	Sep. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Monthly rent payable to Entest	$ 5,000

Stockholders Equity (Details Na

Stockholders Equity (Details Narrative) - $ / shares	12 Months Ended
Stockholders Equity (Details Narrative) - $ / shares	Sep. 30, 2019	Sep. 30, 2018
Common stock, Par value	$ 0.0001	$ 0.0001
Common stock, authorized	4,800,000,000	500,000,000
Common stock issued and outstanding	600,001,406	180,315,107
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	800,000,000	800,000,000
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	600,000	600,000
Preferred stock, shares issued and outstanding	50,000	50,000
Preferred stock, shares outstanding	50,000	50,000
Preferred shares voting	Series AA Preferred Stock
Series M
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	300,000,000	300,000,000
Preferred stock, shares issued and outstanding	38,000,000	38,000,000
Preferred stock, shares outstanding	38,000,000	38,000,000
Preferred shares voting	On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series M Preferred Stock" (hereinafter referred to as "Series M Preferred Stock").
Series A
Preferred stock, non-cumulative cash dividends	$ 0.01
Preferred shares voting	Series A Preferred Stock
Series A Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	300,000,000	300,000,000
Preferred stock, shares issued and outstanding	348,376,230	140,434,496
Preferred stock, shares outstanding	348,376,230	140,434,496

Investment Securities (Details)

Investment Securities (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Prepaid Expenses	$ 76	$ 8,259
Accounts Payable	92,000	$ 80,567
Series M \| Zander Therapeutics
Fair Value of Intellectual Property	1,500
Prepaid Expenses	74,298
Due from Employee	1,071
Note Receivable	64,400
Accrued Interest Receivable	20,274
Investment Securities	593,357
Convertible Note Receivable	10,000
Accounts Payable	1,269,041
Notes Payable	500,000
Accrued Expenses, Related Party	89,529
Accrued Expenses	203,037
Enterprise Value	2,826,507
Less: Total Debt	(2,061,607)
Portion of Enterprise Value attributable to Shareholders	$ 764,900
Fair Value per share	$ 0.0167
Common Stock \| Zander Therapeutics
Fair Value of Intellectual Property	$ 1,500
Prepaid Expenses	74,298
Due from Employee	1,071
Note Receivable	64,400
Accrued Interest Receivable	20,274
Investment Securities	593,357
Convertible Note Receivable	10,000
Accounts Payable	1,269,041
Notes Payable	500,000
Accrued Expenses, Related Party	89,529
Accrued Expenses	203,037
Enterprise Value	2,826,507
Less: Total Debt	(2,061,607)
Portion of Enterprise Value attributable to Shareholders	$ 764,900
Fair Value per share	$ 0.0167

Investment Securities (Details

Investment Securities (Details 1) - USD ($)	12 Months Ended
Investment Securities (Details 1) - USD ($)	Sep. 30, 2019	Sep. 30, 2018
Investment Securities, Fair Value	$ 19,969	$ 166,247
Common Stock \| Zander Therapeutics
Investment Securities, Basis	5,741
Investment Securities, Fair Value	7,858
Investment Securities, Total Unrealized Gain	2,118
Investment Securities, net Unrealized Gain or (Loss) realized	(50,831)
Series M \| Zander Therapeutics
Investment Securities, Basis	13,124
Investment Securities, Fair Value	12,109
Investment Securities, Total Unrealized Gain	(1,104)
Investment Securities, net Unrealized Gain or (Loss) realized	$ (1,104)

Investment Securities (Detail_2

Investment Securities (Details Narrative) - Zander Therapeutics - USD ($)	Jun. 11, 2018	Nov. 29, 2018	Sep. 30, 2019
Number of shares issued for property dividend	470,588		470,588
Series M
Number of shares issued in satisfaction of prepaid rent and accrued interest		725,000	725,000
Shares issued in satisfaction of prepaid rent and accrued interest, value		$ 13,124

Stock Transactions (Details Nar

Stock Transactions (Details Narrative) - USD ($)	Aug. 14, 2019	Aug. 13, 2019	Jul. 12, 2019	Apr. 11, 2019	Apr. 09, 2019	Apr. 08, 2019	Apr. 02, 2019	Apr. 02, 2019	Mar. 04, 2019	Mar. 02, 2019	Feb. 11, 2019	Jan. 09, 2019	Jan. 03, 2019	Oct. 02, 2018	Nov. 20, 2019	Sep. 19, 2019	Jul. 31, 2019	Jun. 27, 2019	May 18, 2019	Apr. 30, 2019	Apr. 29, 2019	Apr. 18, 2019	Mar. 22, 2019	Mar. 19, 2019	Feb. 19, 2019	Feb. 15, 2019	Feb. 13, 2019	Jan. 25, 2019	Jan. 23, 2019	Dec. 26, 2018	Dec. 19, 2018	Nov. 28, 2018	Nov. 28, 2018	Nov. 15, 2018	Oct. 29, 2018	Oct. 23, 2018	Oct. 18, 2018	Jan. 24, 2022
David Koos
Cancellation of Common Shares		5,000,000																									5,000,000											5,000,000
Lander
Cancellation of Common Shares																											5,000,000
Todd Caven
Cancellation of Common Shares		5,000,000																									5,000,000
Harry Lander
Cancellation of Common Shares	5,000,000
Convertible Debt \| Common Stock
Shares issued in satisfaction of convertible identedness			25,870,700	19,472,820	11,832,569	17,971,064	10,000,000	12,992,839	15,000,000	8,004,463	10,473,668		10,585,123	5,128,205		28,517,000	27,161,700		22,000,000	10,000,000	22,243,153	14,824,958	6,309,524	28,210,615	13,790,783	13,821,193		13,100,000	5,774,947	11,000,000	5,184,674	286,232	29,033,181	7,100,591	3,015,618	2,019,940	8,961,988
Value of shares issued in satisdaction of convertible debt			$ 2,049	$ 14,600	$ 8,000	$ 12,100	$ 3,591	$ 8,800	$ 8,756	$ 8,200	$ 12,230		$ 4,607	$ 30,000		$ 2,900	$ 2,962		$ 7,948	$ 2,788	$ 14,800	$ 10,000	$ 5,000	$ 22,504	$ 17,500	$ 15,000		$ 5,975	$ 6,770	$ 7,710	$ 10,000		$ 50,716	$ 30,000	$ 11,000	$ 7,000	$ 30,650
Fees			500				500		500							500	500		500	1,511				$ 500				500		500		$ 500
Accrued Interest			$ 2,883	$ 588	$ 519	$ 1,917	$ 708	$ 554	$ 1,543	$ 444	$ 704		$ 9,153			$ 876	$ 611		$ 352	$ 500	$ 2,549	$ 673	$ 300		$ 2,220	$ 756		$ 991	$ 362	$ 700	$ 447				$ 368	$ 612
Convertible Debt \| Series A Preferred Stock
Shares issued for service, Shares												10,000,000
Shares issued in satisfaction of convertible identedness															3,656,020			194,285,714
Value of shares issued in satisdaction of convertible debt															$ 5,465			$ 340,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 05, 2021	May 03, 2021	Apr. 15, 2021	Apr. 13, 2021	Apr. 13, 2021	Apr. 12, 2021	Mar. 02, 2021	Dec. 16, 2020	Dec. 16, 2020	Dec. 11, 2020	Nov. 06, 2020	Aug. 07, 2020	Jul. 01, 2020	May 12, 2020	Jan. 02, 2020	Jan. 02, 2020	Dec. 13, 2019	Dec. 13, 2019	Dec. 10, 2019	Dec. 06, 2019	Dec. 05, 2019	Dec. 04, 2019	Dec. 03, 2019	Nov. 05, 2019	Nov. 05, 2019	Nov. 05, 2019	Nov. 05, 2019	Jul. 12, 2019	Apr. 11, 2019	Apr. 09, 2019	Apr. 08, 2019	Apr. 02, 2019	Apr. 02, 2019	Mar. 04, 2019	Mar. 02, 2019	Feb. 11, 2019	Jan. 09, 2019	Jan. 03, 2019	Oct. 02, 2018	Apr. 28, 2021	Apr. 21, 2021	Apr. 16, 2021	Apr. 16, 2021	Apr. 15, 2021	Mar. 31, 2021	Mar. 26, 2021	Mar. 18, 2021	Feb. 24, 2021	Feb. 23, 2021	Jan. 28, 2021	Dec. 31, 2020	Dec. 23, 2020	Dec. 17, 2020	Dec. 17, 2020	Oct. 28, 2020	Jan. 23, 2020	Dec. 23, 2019	Dec. 20, 2019	Dec. 20, 2019	Dec. 19, 2019	Dec. 16, 2019	Nov. 27, 2019	Nov. 20, 2019	Nov. 18, 2019	Nov. 15, 2019	Oct. 29, 2019	Oct. 29, 2019	Sep. 19, 2019	Jul. 31, 2019	Jun. 27, 2019	May 18, 2019	Apr. 30, 2019	Apr. 29, 2019	Apr. 18, 2019	Mar. 22, 2019	Mar. 19, 2019	Feb. 19, 2019	Feb. 15, 2019	Jan. 25, 2019	Jan. 23, 2019	Dec. 26, 2018	Dec. 19, 2018	Nov. 28, 2018	Nov. 28, 2018	Nov. 15, 2018	Oct. 29, 2018	Oct. 23, 2018	Oct. 18, 2018	Sep. 30, 2019	Sep. 30, 2018
Common stock, Par value																																																																																									$ 0.0001	$ 0.0001
Common stock, authorized																																																																																									4,800,000,000	500,000,000
Convertible Debt \| Common Stock
Shares issued in satisfaction of convertible identedness																												25,870,700	19,472,820	11,832,569	17,971,064	10,000,000	12,992,839	15,000,000	8,004,463	10,473,668		10,585,123	5,128,205																													28,517,000	27,161,700		22,000,000	10,000,000	22,243,153	14,824,958	6,309,524	28,210,615	13,790,783	13,821,193	13,100,000	5,774,947	11,000,000	5,184,674	286,232	29,033,181	7,100,591	3,015,618	2,019,940	8,961,988
Value of shares issued in satisdaction of convertible debt																												$ 2,049	$ 14,600	$ 8,000	$ 12,100	$ 3,591	$ 8,800	$ 8,756	$ 8,200	$ 12,230		$ 4,607	$ 30,000																													$ 2,900	$ 2,962		$ 7,948	$ 2,788	$ 14,800	$ 10,000	$ 5,000	$ 22,504	$ 17,500	$ 15,000	$ 5,975	$ 6,770	$ 7,710	$ 10,000		$ 50,716	$ 30,000	$ 11,000	$ 7,000	$ 30,650
Accrued Interest																												$ 2,883	$ 588	$ 519	$ 1,917	$ 708	$ 554	$ 1,543	$ 444	$ 704		$ 9,153																														$ 876	$ 611		$ 352	$ 500	$ 2,549	$ 673	$ 300		$ 2,220	$ 756	$ 991	$ 362	$ 700	$ 447				$ 368	$ 612
Convertible Debt \| Series A Preferred Stock
Shares issued in satisfaction of convertible identedness																																																															3,656,020							194,285,714
Value of shares issued in satisdaction of convertible debt																																																															$ 5,465							$ 340,000
Sales of stock for consideration, shares																																					10,000,000
Subsequent Event [Member] \| Convertible Debt \| Common Stock
Shares issued in satisfaction of convertible identedness	27,753,016	33,012,555	49,482,000	83,636,833	32,968,042	85,000,000	119,269,538	88,158,923	6,437,153	87,020,000	83,934,153				69,685,185	70,793,000	52,214,500	52,200,000	49,729,272	41,923,556	41,922,222	36,542,564	36,114,111	29,219,194	28,000,000	28,000,000	30,555,555													28,784,167	163,814,000	90,311,411	70,755,885	146,452,000	40,000,000		70,000,000	82,759,286	88,000,000	85,900,000	117,837,384	108,444,444		83,216,917	80,065,846	42,035,947	59,907,667	59,940,000	59,900,000	42,000,000	49,759,153	36,500,000				24,253,038	19,475,615
Value of shares issued in satisdaction of convertible debt	$ 1,187	$ 1,416	$ 2,288	$ 3,511	$ 19,000	$ 3,111	$ 5,260	$ 4,030	$ 852	$ 7,300	$ 3,900				$ 3,763	$ 1,104	$ 2,266	$ 3,132	$ 5,878	$ 907	$ 7,456	$ 6,090	$ 5,500	$ 9,000	$ 5,775	$ 5,775	$ 11,000													$ 22,000	$ 7,564	$ 4,238	$ 47,000	$ 1,416	$ 1,926		$ 3,415	$ 30,000	$ 4,400	$ 5,154	$ 5,330	$ 16,000		$ 8,200	$ 3,752	$ 202	$ 942	$ 3,280	$ 3,594	$ 3,280	$ 5,470	$ 2,785				$ 10,000	$ 4,907
Accrued Interest	$ 616	$ 729	$ 680	$ 1,508	$ 4,736	$ 49	$ 2,492	$ 1,700	$ 429	$ 3,142	$ 1,555					524	366			$ 2,365		$ 1,035		$ 1,518	$ 2,625	$ 2,625														$ 3,905	$ 2,264	$ 17	$ 8,189	$ 680	$ 74		$ 84	$ 4,758			$ 2,329	$ 3,250		$ 1,786	$ 1,452	558	354	$ 616			$ 988	$ 500				$ 1,035	$ 1,422
Fees																$ 500	$ 500																																							$ 500	$ 500
Subsequent Event [Member] \| Convertible Debt \| Series A Preferred Stock
Shares issued in satisfaction of convertible identedness												16,549,800	11,603,784	5,238,875																																							32,379,169
Value of shares issued in satisdaction of convertible debt												$ 7,000	$ 5,000	$ 3,000																																							$ 13,000
Accrued Interest												$ 3,757	$ 2,542	$ 1,426																																							$ 8,046
Subsequent Event [Member] \| Convertible Debt \| Series M Preferred Stock
Sales of stock for consideration, shares																																																																2,000,000	4,000,000
Subsequent Event [Member] \| Convertible Debt \| Series NC Preferred Stock
Common stock, Par value																																														$ 0.0001
Common stock, authorized																																														20,000
Number of non voting convertible preferred stock sold																																														500,000
Sales of stock for consideration, shares				10,000